SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Adverum Biotechnologies, Inc. – ‘10-K’ for 12/31/20 – ‘EX-23.1’

On:  Monday, 3/1/21, at 4:12pm ET   ·   For:  12/31/20   ·   Accession #:  1628280-21-3623   ·   File #:  1-36579

Previous ‘10-K’:  ‘10-K’ on 3/12/20 for 12/31/19   ·   Next:  ‘10-K’ on 3/29/22 for 12/31/21   ·   Latest:  ‘10-K’ on 3/18/24 for 12/31/23   ·   29 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/01/21  Adverum Biotechnologies, Inc.     10-K       12/31/20   79:8.6M                                   Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.24M 
 2: EX-4.2      Instrument Defining the Rights of Security Holders  HTML     36K 
 3: EX-21.1     Subsidiaries List                                   HTML     23K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     23K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
15: R1          Cover Page                                          HTML     87K 
16: R2          Consolidated Balance Sheets                         HTML     88K 
17: R3          Consolidated Balance Sheets (Parenthetical)         HTML     40K 
18: R4          Consolidated Statements of Operations and           HTML     69K 
                Comprehensive Loss                                               
19: R5          Consolidated Statements of Stockholders' Equity     HTML     97K 
20: R6          Consolidated Statements of Stockholders' Equity     HTML     25K 
                (Parenthetical)                                                  
21: R7          Consolidated Statements of Cash Flows               HTML    114K 
22: R8          Description of the Business                         HTML     26K 
23: R9          Summary of Significant Accounting Policies          HTML     55K 
24: R10         Fair Value Measurements and Fair Value of           HTML     65K 
                Financial Instruments                                            
25: R11         Revenue                                             HTML     28K 
26: R12         Leases                                              HTML     33K 
27: R13         Balance Sheet Components                            HTML     43K 
28: R14         Financing Arrangements                              HTML     25K 
29: R15         Commitments and Contingencies                       HTML     26K 
30: R16         Common Stock Warrants                               HTML     29K 
31: R17         Stock Plans                                         HTML     98K 
32: R18         401(k) Savings Plan                                 HTML     25K 
33: R19         Income Taxes                                        HTML     97K 
34: R20         Net Loss per Share                                  HTML     33K 
35: R21         Related Party Transactions                          HTML     25K 
36: R22         Subsequent Events                                   HTML     33K 
37: R23         Summary of significant accounting policies          HTML    103K 
                (Policies)                                                       
38: R24         Fair Value Measurements and Fair Value of           HTML     59K 
                Financial Instruments (Tables)                                   
39: R25         Leases (Tables)                                     HTML     37K 
40: R26         Balance Sheet Components (Tables)                   HTML     45K 
41: R27         Common Stock Warrants (Tables)                      HTML     30K 
42: R28         Stock Plans (Tables)                                HTML     99K 
43: R29         Income Taxes (Tables)                               HTML    102K 
44: R30         Net Loss per Share (Tables)                         HTML     34K 
45: R31         Subsequent Events (Tables)                          HTML     38K 
46: R32         Description of the Business - Additional            HTML     25K 
                Information (Detail)                                             
47: R33         Summary of Significant Accounting Policies -        HTML     41K 
                Additional Information (Detail)                                  
48: R34         Fair Value Measurements and Fair Value of           HTML     27K 
                Financial Instruments - Additional Information                   
                (Detail)                                                         
49: R35         Fair Value Measurements and Fair Value of           HTML     54K 
                Financial Instruments - Summary of Cash                          
                Equivalents and Short-term Investments (Detail)                  
50: R36         Revenue - Additional Information (Detail)           HTML     41K 
51: R37         Leases - Additional Information (Detail)            HTML     48K 
52: R38         Leases - Schedule of Future Non-cancellable Lease   HTML     41K 
                Payments under Operating Lease (Detail)                          
53: R39         Balance Sheet Components - Schedule of Property     HTML     42K 
                and Equipment, Net (Detail)                                      
54: R40         Balance Sheet Components - Additional Information   HTML     25K 
                (Detail)                                                         
55: R41         Balance Sheet Components - Schedule of Accrued      HTML     36K 
                Expenses and Other Current Liabilities (Detail)                  
56: R42         Financing Arrangements - Additional Information     HTML     32K 
                (Detail)                                                         
57: R43         Commitments and Contingencies (Detail)              HTML     36K 
58: R44         Common Stock Warrants - Outstanding Warrants to     HTML     34K 
                Purchase Common Stock (Detail)                                   
59: R45         Common Stock Warrants - Additional Information      HTML     30K 
                (Detail)                                                         
60: R46         Stock Plans - Additional Information (Detail)       HTML     85K 
61: R47         Stock Plans - Summary of Stock Options Activity     HTML     73K 
                (Detail)                                                         
62: R48         Stock Plans - Schedule of Stock Purchase Plan       HTML     38K 
                Valuation Assumptions (Detail)                                   
63: R49         Stock Plans - Summary of Restricted Stock Units     HTML     52K 
                Activity (Detail)                                                
64: R50         Stock Plans - Stock-Based Compensation Expense      HTML     30K 
                (Detail)                                                         
65: R51         401(k) Savings Plan - Additional Information        HTML     24K 
                (Detail)                                                         
66: R52         Income Taxes - Schedule of Components of Income     HTML     37K 
                Tax Provision (Benefit) (Details)                                
67: R53         Income Taxes - Schedule of Components of Loss       HTML     30K 
                Before Income Taxes (Detail)                                     
68: R54         Income Taxes - Schedule of Reconciliation of        HTML     50K 
                Income Tax Expense Computed Statutory Federal                    
                Income Tax and Financial Statements (Detail)                     
69: R55         Income Taxes - Schedule of Deferred Tax Assets      HTML     58K 
                (Detail)                                                         
70: R56         Income Taxes - Additional Information (Detail)      HTML     47K 
71: R57         Income Taxes - Schedule of Unrecognized Tax         HTML     32K 
                Benefits (Detail)                                                
72: R58         Net Loss per Share - Schedule of Antidilutive       HTML     36K 
                Common Stock Equivalents Excluded from Calculation               
                of Diluted Net Loss Per Share (Detail)                           
73: R59         Related Party Transactions - Additional             HTML     35K 
                Information (Detail)                                             
74: R60         Subsequent Events - Additional Information          HTML     56K 
                (Detail)                                                         
75: R61         Subsequent Event - Schedule of Undiscounted Future  HTML     43K 
                Non-cancellable Lease Payments (Details)                         
77: XML         IDEA XML File -- Filing Summary                      XML    138K 
14: XML         XBRL Instance -- advm-20201231_htm                   XML   1.52M 
76: EXCEL       IDEA Workbook of Financial Reports                  XLSX     90K 
10: EX-101.CAL  XBRL Calculations -- advm-20201231_cal               XML    225K 
11: EX-101.DEF  XBRL Definitions -- advm-20201231_def                XML    454K 
12: EX-101.LAB  XBRL Labels -- advm-20201231_lab                     XML   1.48M 
13: EX-101.PRE  XBRL Presentations -- advm-20201231_pre              XML    835K 
 9: EX-101.SCH  XBRL Schema -- advm-20201231                         XSD    137K 
78: JSON        XBRL Instance as JSON Data -- MetaLinks              321±   496K 
79: ZIP         XBRL Zipped Folder -- 0001628280-21-003623-xbrl      Zip    800K 


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 23.1



CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statements on Form S-8 Nos. 333-223894, 333-218465, 333-211439, 333-203398, 333-199296, 333-230138, 333-233135, 333-220894, 333-237136 and 333-243761
(2)Registration Statements on Form S-3 Nos. 333-219890 and 333-233134

of our reports dated March 1, 2021, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. and the effectiveness of internal control over financial reporting of Adverum Biotechnologies, Inc. included in this Annual Report (Form 10-K) of Adverum Biotechnologies Inc. for the year ended December 31, 2020.



/s/ Ernst & Young LLP

San Jose, California
March 1, 2021


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/1/218-K,  S-8
For Period end:12/31/20
 List all Filings 


13 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  Adverum Biotechnologies, Inc.     S-3                    6:637K                                   Donnelley … Solutions/FA
 3/20/24  Adverum Biotechnologies, Inc.     424B3                  1:178K                                   Donnelley … Solutions/FA
 3/18/24  Adverum Biotechnologies, Inc.     10-K       12/31/23   74:12M                                    Workiva Inc Wde… FA01/FA
 3/18/24  Adverum Biotechnologies, Inc.     S-8         3/18/24    4:84K                                    Donnelley … Solutions/FA
 3/04/24  Adverum Biotechnologies, Inc.     S-3                    4:276K                                   Donnelley … Solutions/FA
 5/11/23  Adverum Biotechnologies, Inc.     424B5                  1:434K                                   Donnelley … Solutions/FA
 4/25/23  Adverum Biotechnologies, Inc.     S-3                    7:734K                                   Donnelley … Solutions/FA
 3/30/23  Adverum Biotechnologies, Inc.     10-K       12/31/22   73:8.2M                                   Workiva Inc Wde… FA01/FA
 3/30/23  Adverum Biotechnologies, Inc.     S-8         3/30/23    4:80K                                    Donnelley … Solutions/FA
 8/11/22  Adverum Biotechnologies, Inc.     S-8         8/11/22    4:81K                                    Donnelley … Solutions/FA
 3/29/22  Adverum Biotechnologies, Inc.     10-K       12/31/21   75:10M                                    Workiva Inc Wde… FA01/FA
 3/29/22  Adverum Biotechnologies, Inc.     S-8         3/29/22    4:83K                                    Donnelley … Solutions/FA
 3/01/21  Adverum Biotechnologies, Inc.     S-8         3/01/21    4:174K                                   Donnelley … Solutions/FA


16 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/10/20  Adverum Biotechnologies, Inc.     10-Q        6/30/20   53:5.9M                                   Workiva Inc Wde… FA01/FA
 5/28/20  Adverum Biotechnologies, Inc.     10-Q        3/31/20   47:4.2M                                   Workiva Inc Wde… FA01/FA
12/16/19  Adverum Biotechnologies, Inc.     8-K:5,9    12/13/19    2:195K                                   Donnelley … Solutions/FA
11/07/19  Adverum Biotechnologies, Inc.     10-Q        9/30/19   56:5.6M                                   ActiveDisclosure/FA
 5/08/19  Adverum Biotechnologies, Inc.     10-Q        3/31/19   47:4.1M                                   ActiveDisclosure/FA
 3/06/19  Adverum Biotechnologies, Inc.     10-K       12/31/18   88:12M                                    ActiveDisclosure/FA
 8/08/18  Adverum Biotechnologies, Inc.     10-Q        6/30/18   48:5.7M                                   ActiveDisclosure/FA
 3/06/18  Adverum Biotechnologies, Inc.     10-K       12/31/17  102:13M                                    ActiveDisclosure/FA
10/11/17  Adverum Biotechnologies, Inc.     S-8        10/11/17    6:246K                                   Donnelley … Solutions/FA
 6/02/17  Adverum Biotechnologies, Inc.     S-8         6/02/17    5:240K                                   Donnelley … Solutions/FA
 3/09/17  Adverum Biotechnologies, Inc.     10-K       12/31/16   97:13M                                    ActiveDisclosure/FA
 8/09/16  Adverum Biotechnologies, Inc.     10-Q        6/30/16   74:8.3M                                   ActiveDisclosure/FA
 5/12/16  Adverum Biotechnologies, Inc.     8-K:1,2,3,5 5/11/16    8:573K                                   Donnelley … Solutions/FA
11/20/15  Adverum Biotechnologies, Inc.     8-K:5,7,9  11/19/15    5:267K                                   Donnelley … Solutions/FA
 7/25/14  Adverum Biotechnologies, Inc.     S-1/A                 11:1.4M                                   Donnelley … Solutions/FA
 7/18/14  Adverum Biotechnologies, Inc.     S-1/A¶                10:4.4M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001628280-21-003623   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 2:02:50.3pm ET